Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

‘Weight loss drugs should not be seen as a silver bullet’ says RCGP chair

Weight loss drugs do not come without risk
A woman makes a weekly subcutaneous injection of Semaglutide in the stomach for the treatment of type 2 diabetes (gettyimages)

She warned that the tirzepatide rollout could lead to an additional 1,000,000 GP appointments, with a quarter of a million people expected to receive the weight loss drug in the first phase 

Professor Kamila Hawthorne, chair of the Royal College of GPs, has cautioned that while weight loss drugs hold significant potential to enhance many patients' lives, they are not without risks.

She also expressed concern that expanding the roll out of tirzepatide at the scale proposed by the National Institute for Health and Care Excellence (NICE) would have “significant practical and resource implications for the NHS and primary care.”


The final draft guidance from NICE, published on 5 December, suggests that around 220,000 people living with obesity will be offered the weekly injection, along with a reduced-calorie diet and increased physical activity, over the next three years.

Marketed under the brand name Mounjaro by Eli Lilly, tirzepatide is recommended for people with a body mass index (BMI) of more than 35 and at least one weight-related illness.

Accepting the request from NHS England to roll out the medication over 12 years, the NICE guidance proposes to prioritise those with the highest clinical need.

This includes people who are already receiving care in specialist weight management services and they will be able to access tirzepatide within 90 days of NICE's final guidance being published, if clinically eligible.

NHS England will develop a plan detailing which other groups of patients will be offered tirzepatide in the next three years.

Professor Jonathan Benger, NICE’s chief medical officer said: “The world will look very different in three years which is why we’ve taken the unprecedented decision to review the way this medicine is delivered to patients then.

“Tirzepatide and other drugs like it, such as semaglutide, will help people living with obesity to lose weight, and as a result will reduce their risk of developing heart disease or having a stroke.”

Weight loss drugs do not come without risk  

Professor Hawthorne acknowledged that these weight loss drugs have shown benefits for certain patients and offer a lot of potential to improve the lives of many, particularly those with health conditions linked to their weight.

However, she cautioned that these medications should not be seen as a “silver bullet for weight loss” as they come with risks and there is “no one-size fits all approach to tackling obesity.”

She emphasised the importance of placing as much, if not more, focus on prevention and stopping people from becoming overweight, rather than relying solely on medical interventions.

Professor Hawthorne also noted that expanding the number of patients eligible for weight loss jabs should not be seen as an alternative to properly resourcing other services designed to help patients lose weight, such as those that support lifestyle changes, weight loss clinics, and bariatric surgery.

“Different patients will respond to different interventions, so these services need to work alongside each other.

“We also don’t know how long tirzepatide should be taken for, as it appears that when it is stopped, weight gain can recur,” she said.

Professor Hawthorne added that, as more patients become eligible for tirzepatide, serious consideration must be given to the impact this will have on general practice.

“If 220,000 patients are going to receive this treatment, even over a period of three years, that could be up to an additional 1,000,000 GP appointments.

“It’s vital that general practice is resourced appropriately, and that GPs have the necessary training to safely take on any additional responsibility that comes their way,” she noted.

Professor Hawthorne urged people not to acquire and take weight loss medication without a prescription and from dubious sources online, warning that this can be “incredibly dangerous.”

Tirzepatide: Benefits and costs

Clinical trials have shown tirzepatide to be more effective than diet and exercise alone and compared to semaglutide with diet and exercise, with patients losing an average of 21 per cent of their body weight in 36 weeks.

Kwik Pens are £122 each at the highest 15mg dose, with each pen containing 4 doses, providing a 4-week supply.

It is estimated that the medicine and associated wraparound care services will cost NHS England around £317.2m per year by the third year of implementation.

Despite the significant cost, evidence suggests that the treatment is cost-effective for some patients, as weight loss in those with obesity-related illnesses reduces the risk of further health complications, ultimately saving the NHS money.

Despite the considerable cost, evidence suggests the treatment is cost-effective for some patients, as weight loss in those with obesity-related illnesses reduces the risk of further health complications, ultimately saving the NHS money.

Dr Kath McCullough, NHS England’s national specialty advisor for obesity, stated that weight loss drugs are an important tool in helping people lose weight while also reducing the risk of other serious long-term conditions such as diabetes, strokes and heart attacks.

However, she warned that these drugs, on their own, are not a magic bullet and they need to be prescribed by a healthcare professional alongside programmes that help people lose weight and live healthier lives by making changes to their diet and physical activity.

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less